MACROH2A1

Across TCGA pan-cancer cohorts, MACROH2A1 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated MACROH2A1 data layer compared with 22 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher MACROH2A1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated MACROH2A1 expression acts as an unfavorable survival marker, although some lineages such as GBM and CCRCC show a favorable association.

LUAD, GBM, and OV are the cancer types where MACROH2A1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	All	0.865	0.968	.001	22	view →
GBM	OS	Median	All	0.580	0.253	.006	10	view →
OV	DFS	Median	All	0.614	1.000	.005	4	view →
CCRCC	DFS	Quartile	II,III,IV	1.000	0.199	.049	4	view →
LSCC	DFS	Quartile	III,IV	0.406	1.000	.013	4	view →
PDAC	DFS	Tertile	II,III,IV	0.621	0.382	.028	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

MACROH2A1–LUAD (DFS)

Open the LUAD breakdown →